Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR 49.38
+0.07 (0.14%)
Sep 24, 2026, 5:35 PM CET
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 10.87B EUR in the quarter ending June 30, 2026, with 1.24% growth. This brings the company's revenue in the last twelve months to 45.38B, down -1.73% year-over-year. In the year 2025, Bayer Aktiengesellschaft had annual revenue of 45.58B, down -2.21%.
Revenue (ttm)
45.38B
Revenue Growth
-1.73%
P/S Ratio
1.07
Revenue / Employee
516.62K
Employees
87,830
Market Cap
48.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.58B | -1.03B | -2.21% |
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | 43.55B | 6.80B | 18.52% |
| Dec 31, 2018 | 36.74B | 1.73B | 4.93% |
| Dec 31, 2017 | 35.02B | 72.00M | 0.21% |
| Dec 31, 2016 | 34.94B | -11.14B | -24.18% |
| Dec 31, 2015 | 46.09B | 4.75B | 11.48% |
| Dec 31, 2014 | 41.34B | 1.18B | 2.94% |
| Dec 31, 2013 | 40.16B | 416.00M | 1.05% |
| Dec 31, 2012 | 39.74B | 3.21B | 8.80% |
| Dec 31, 2011 | 36.53B | 1.44B | 4.10% |
| Dec 31, 2010 | 35.09B | 3.92B | 12.58% |
| Dec 31, 2009 | 31.17B | -1.75B | -5.32% |
| Dec 31, 2008 | 32.92B | 533.00M | 1.65% |
| Dec 31, 2007 | 32.39B | 32.19B | 16,422.96% |
| Dec 31, 2006 | 196.00M | -24.51B | -99.21% |
| Dec 31, 2005 | 24.70B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Fresenius Medical Care AG | 19.43B |
| Sartorius Aktiengesellschaft | 3.58B |
| Drägerwerk AG & Co. KGaA | 3.57B |
| Fielmann Group AG | 2.46B |
| Carl Zeiss Meditec AG | 2.18B |
Bayer Aktiengesellschaft News
- 1 day ago - Bayer to sell cancer drug Stigvarga for up to $431M, WSJ reports - TheFly
- 3 days ago - Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million - WSJ
- 7 days ago - Robigo announces Series A funding led by Leaps by Bayer - TheFly
- 7 days ago - Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs - Business Wire
- 7 days ago - Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes - TheFly
- 7 days ago - Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes - Business Wire
- 9 days ago - Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement - Reuters
- 13 days ago - Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court - Reuters